Egypt · Delayed Price · Currency is EGP GlaxoSmithKline S.A.E Statistics
Total Valuation
EGX:BIOC has a market cap or net worth of EGP 5.29 billion. The enterprise value is 6.21 billion.
| Market Cap | 5.29B |
| Enterprise Value | 6.21B |
Important Dates
The last earnings date was Thursday, November 13, 2025.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
EGX:BIOC has 83.51 million shares outstanding. The number of shares has increased by 0.69% in one year.
| Current Share Class | 83.51M |
| Shares Outstanding | 83.51M |
| Shares Change (YoY) | +0.69% |
| Shares Change (QoQ) | -2.16% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 2.43M |
Valuation Ratios
The trailing PE ratio is 54.06.
| PE Ratio | 54.06 |
| Forward PE | n/a |
| PS Ratio | 1.41 |
| PB Ratio | 2.60 |
| P/TBV Ratio | 2.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 27.44, with an EV/FCF ratio of -31.35.
| EV / Earnings | 63.16 |
| EV / Sales | 1.66 |
| EV / EBITDA | 27.44 |
| EV / EBIT | 36.97 |
| EV / FCF | -31.35 |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.53 |
| Quick Ratio | 0.41 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | 5.59 |
| Debt / FCF | -6.38 |
| Interest Coverage | 12.70 |
Financial Efficiency
Return on equity (ROE) is 4.97% and return on invested capital (ROIC) is 3.58%.
| Return on Equity (ROE) | 4.97% |
| Return on Assets (ROA) | 2.55% |
| Return on Invested Capital (ROIC) | 3.58% |
| Return on Capital Employed (ROCE) | 8.00% |
| Revenue Per Employee | 4.68M |
| Profits Per Employee | 122,952 |
| Employee Count | 800 |
| Asset Turnover | 0.91 |
| Inventory Turnover | 2.35 |
Taxes
In the past 12 months, EGX:BIOC has paid 112.01 million in taxes.
| Income Tax | 112.01M |
| Effective Tax Rate | 53.24% |
Stock Price Statistics
The stock price has increased by +55.17% in the last 52 weeks. The beta is 0.98, so EGX:BIOC's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | +55.17% |
| 50-Day Moving Average | 65.96 |
| 200-Day Moving Average | 48.62 |
| Relative Strength Index (RSI) | 40.31 |
| Average Volume (20 Days) | 73,053 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, EGX:BIOC had revenue of EGP 3.74 billion and earned 98.36 million in profits. Earnings per share was 1.17.
| Revenue | 3.74B |
| Gross Profit | 597.87M |
| Operating Income | 168.06M |
| Pretax Income | 210.38M |
| Net Income | 98.36M |
| EBITDA | 213.43M |
| EBIT | 168.06M |
| Earnings Per Share (EPS) | 1.17 |
Balance Sheet
The company has 342.82 million in cash and 1.26 billion in debt, giving a net cash position of -921.85 million or -11.04 per share.
| Cash & Cash Equivalents | 342.82M |
| Total Debt | 1.26B |
| Net Cash | -921.85M |
| Net Cash Per Share | -11.04 |
| Equity (Book Value) | 2.03B |
| Book Value Per Share | 24.35 |
| Working Capital | 1.29B |
Cash Flow
In the last 12 months, operating cash flow was -57.87 million and capital expenditures -140.30 million, giving a free cash flow of -198.17 million.
| Operating Cash Flow | -57.87M |
| Capital Expenditures | -140.30M |
| Free Cash Flow | -198.17M |
| FCF Per Share | -2.37 |
Margins
Gross margin is 15.98%, with operating and profit margins of 4.49% and 2.63%.
| Gross Margin | 15.98% |
| Operating Margin | 4.49% |
| Pretax Margin | 5.62% |
| Profit Margin | 2.63% |
| EBITDA Margin | 5.71% |
| EBIT Margin | 4.49% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.75, which amounts to a dividend yield of 1.18%.
| Dividend Per Share | 0.75 |
| Dividend Yield | 1.18% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 14.36% |
| Buyback Yield | -0.69% |
| Shareholder Yield | 0.50% |
| Earnings Yield | 1.86% |
| FCF Yield | -3.75% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
EGX:BIOC has an Altman Z-Score of 2.51 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.51 |
| Piotroski F-Score | 3 |